Summary
During the development of tumors, autoantibodies against aberrant or overexpressed autoantigens can be induced. Several hundreds of tumor-associated autoantibodies (TAAB) with more or less specificity for tumors have been found until now by molecular cloning and proteomics technologies. Many TAAB are detectable in preclinical stages of the disease and may be indicators of tumor development. The screening for autoantibody responses in tumor patients may lead to new diagnostic tumor markers and may be a simple and effective way to identify concomitantly cytotoxic T-lymphocyte (CTL) reactivity. However, most of the TAAB lack sufficient sensitivity and specificity for use as biomarkers in the clinical practice. For further use TAAB should be selected for their specificity regarding malignancies and for their potential clinical application. If selected for high specificity, for the screening of risk groups the sensitivities of most TAAB are too low. A combined determination of two or more tumor-specific autoantibodies may overcome this problem. Therefore, a further evaluation of the relevance of known autoantibody specificities as well as the search for novel diagnostically relevant TAAB by different methodologies is necessary. An optimal combination of highly specific TAAB in multiparametric assays as well as the standardization of the autoantibody analysis is necessary to exhaust the potential of TAAB in the early (presymptomatic) diagnosis and monitoring of malignancies.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Conrad K, Roggenbuck D, Bachmann M. (2005) Autoantibodies as indicators of tumor development. In: Conrad K, Bachmann M, Lehmann W, Sack U (Eds). Methods, Possibilities and Perspectives of Pre-symptomatic Tumor Diagnostics. Pabst Science Publishers, Lengerich, pp 55–77.
Tan EM. (2001) Autoantibodies as reporters identifying aberrant cellular mechanism in tumorigenesis. J Clin Invest; 108:1411–1415.
Jaeger E, Chen YT, Drijfhout JW, Karbach J, Ringhoffer M, Jaeger D, Arand M, Wada H, Noguchi Y, Stockert E, Old LJ, Knuth A. (1998) Simultaneous humoral and cellular immune response against cancer-testis antigen NY-ESO-1: Definition of human histocompatibility leukocyte antigen (HLA)-A2-binding peptide epitopes. J Exp Med; 187:265–270.
Conrad K. (2000) Autoantibodies in cancer patients and in persons with a higher risk of cancer development. In: Shoenfeld, Y, Gershwin ME (Eds). Cancer and Autoimmunity. Elsevier, Amsterdam, pp 159–173.
Crawford LV, Pim DC, Bulbrook RD. (1982) Detection of antibodies against the cellular protein p53 in sera from patients with breast cancer. Int J Cancer; 30:403–408.
Lubin R, Zalcman G, Bouchet L, Tredanel J, Legros Y, Cazals D, Hirsch A, Soussi T. (1995) Serum p53 antibodies as early markers of lung cancer. Nature Med; 1:701–702.
Trivers GE, De Benedetti VMG, Cawley HL, Caron G, Harrington AM, Bennett WP, Jett JR, Colby TV, Tazelaar H, Pairolero P, Miller RD, Harris CC. (1996) Anti-p53 antibodies in sera from patients with chronic obstructive pulmonary disease can predate a diagnosis of cancer. Clin Cancer Res; 2:1767–1775.
Rohayem J, Diestelkoetter P, Weigle B, Oehmischen A, Schmitz M, Mehlhorn J, Conrad K, Rieber EP (2000) Antibody response to the tumor-associated inhibitor of apoptosis protein Survivin in cancer patients. Cancer Res; 60:1815–1817.
Tomkiel JE, Alansari H, Tang N, Virgin JB, Yang X, VandeVord P, Karvonen RL, Granda JL, Kraut MJ, Ensley JF, Fernández-Madrid F. (2002) Autoimmunity to the Mr 32,000 subunit of replication protein A in breast cancer. Clin Cancer Res; 8:752–758.
Himoto T, Kuriyama S, Zhang JY, Chan EKL, Nishioka M, Tan EM. (2005) Significance of autoantibodies against insulin-like growth factor II mRNA-binding proteins in patients with hepatocellular carcinoma. Int J Oncol; 26:311–317.
Frenkel K, Karkoszka J, Glassman T, Dubin N, Toniolo P, Taioli E. (1998) Mooney LA, Kato I: Serum autoantibodies recognizing 5-hydroxymethyl-2’-deoxyuridine, an oxidized DNA base, as biomarkers of cancer risk in women. Cancer Epidemiol Biomarkers Prev; 7:49–57.
Old LJ. (1981) Cancer immunology: The search for specificity - G.H.A. Lowes Memorial Lecture. Cancer Res; 41:361–375.
Old LJ, Chen YT. (1998) New paths in human cancer serology. J Exp Med; 187:1163–1167.
Tröster H, Metzger TE, Semsei I, Schwemmle M, Winterpacht A, Zabel B, Bachmann M. (1994) One gene, two transcripts: Isolation of an alternative transcript encoding for the autoantigen La/SS-B from a cDNA library of a patient with primary Sjögrens’ syndrome. J Exp Med; 180:2059–2067.
Sahin U, Türeci O, Schmitt H, Cochlovius B, Johannes T, Schmits R, Stenner F, Luo G, Schobert I, Pfreundschuh M. (1995) Human neoplasms elicit multiple specific immune responses in the autologous host. Proc Natl Acad Sci USA; 92:11810–11813.
Acknowledgments
We thank Uta Kießling, Andrea Thieme, and Martina Franke for their excellent technical support.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2009 Humana Press, a part of Springer Science+Business Media, LLC
About this protocol
Cite this protocol
Conrad, K., Bartsch, H., Canzler, U., Pilarsky, C., Grützmann, R., Bachmann, M. (2009). Search for and Identification of Novel Tumor-Associated Autoantigens. In: Grützmann, R., Pilarsky, C. (eds) Cancer Gene Profiling. Methods in Molecular Biology, vol 576. Humana Press. https://doi.org/10.1007/978-1-59745-545-9_12
Download citation
DOI: https://doi.org/10.1007/978-1-59745-545-9_12
Published:
Publisher Name: Humana Press
Print ISBN: 978-1-934115-76-3
Online ISBN: 978-1-59745-545-9
eBook Packages: Springer Protocols